ORYZON HA elevated its losses to 3.7 million euros in 2024which means worsening the accounts of 2023 in 0.3 million, due to «a lower monetization of tax deductions derived from an increase in the intensity of clinical studies carried out in the US». For its part, The income related to work done for the immobilized themselves have risen to 7.4 millionand the firm has made investments in R&D for an amount of 8.3 million, of which 7.6 million correspond to development and 0.7 million to investigation. After the completion of the portico clinical trial, the intensity in R&D investments has been reduced by 6.7 million compared to December 31, 2023. At the end of the fourth quarter of 2024 Cash and financial investments available amount to 5.6 million of euros.
Carlos BuesaCEO of Oryzon, ensures that «the publication of the final data of the Reimagine Study on Authority, ADHD and Limit Personality Disorder (FTA) in a prestigious specialized magazine has allowed the scientific community and investment to contextualize and better appreciate the relevance of Vafidemstat's results in the treatment of aggressiveness in our phase Iib portico essay«.» As we mentioned in the previous note, We have received the official minutes of our phase II final meeting with the FDA, confirming that we can move to a phase III. The FDA also indicated that the agitation/aggressiveness in TLP can be an acceptable indication and that we can use the same scale to measure aggressiveness that showed the strongest signal in phase II, «he adds.